IL1R1 and plasma cell myeloma: For example, monoclonal antibodies that block IL-1R (e.g., anakinra, rilonacept, canakinumab, and gevokizumab) have been used to impair IL-1α- and IL-1β-mediated signaling via IL-1R, for the prevention or treatment of multiple myeloma through inhibition of IL-1β-induced production of IL-6 (72).